Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04123795 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis
A Phase 3 study of Moderate Chronic Plaque Psoriasis and Severe Chronic Plaque Psoriasis, sponsored by UCB Biopharma SRL.
- Active
- Registry status
- Phase 3
- Development phase
- 49
- Enrollment target
- 19
- Study locations
NCT04123795: Active Phase 3 study of Moderate Chronic Plaque Psoriasis and Severe Chronic Plaque Psoriasis, sponsored by UCB Biopharma SRL.
NCT04123795 is a Phase 3 study of Moderate Chronic Plaque Psoriasis and Severe Chronic Plaque Psoriasis that is active but no longer recruiting, run by UCB Biopharma SRL. The registered enrollment target is 49 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower). The trial reports 19 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04123795, a Phase 3 study of Moderate Chronic Plaque Psoriasis and Severe Chronic Plaque Psoriasis, is active but no longer recruiting, sponsored by UCB Biopharma SRL.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 49 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.
Primary Outcome
Blood samples will be collected for measurement of plasma concentrations of CZP at Week 16.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Certolizumab pegol
Study Locations (19)
Florida
- Ps0007 50217 - Boca Raton
- Ps0007 50248 - Hialeah
- Ps0007 50169 - Jacksonville
- Ps0007 50268 - Miami
- Ps0007 50269 - Wellington
Other
- Ps0007 50183 - Calgary
- Ps0007 50225 - Calgary
- Ps0007 50187 - Edmonton
- Ps0007 50265 - San Juan
California
- Ps0007 50162 - Fountain Valley
- Ps0007 50161 - Los Angeles
- Ps0007 50196 - Thousand Oaks
Texas
- Ps0007 50156 - Arlington
- Ps0007 50277 - San Antonio
Arizona
- Ps0007 50175 - Phoenix
Georgia
- Ps0007 50230 - Rome
Illinois
- Ps0007 50168 - Chicago
Kansas
- Ps0007 50286 - Topeka
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2020-01-21 |
| Est. Completion | 2034-08-15 |
| Phase | Phase 3 |
What the registry record for NCT04123795 still lists
NCT04123795 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Moderate Chronic Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04123795 lists 19 locations in 9 states (Florida, Other, California).
Frequently Asked Questions
What is clinical trial NCT04123795 about?
NCT04123795 is a clinical study titled "A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis". The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.
What is the current status of trial NCT04123795?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 49 participants. The study started on 2020-01-21. Estimated completion is 2034-08-15.
What conditions does trial NCT04123795 study?
This clinical trial studies the following conditions: Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis.
What interventions are being tested in trial NCT04123795?
The interventions under investigation include: Placebo (DRUG), Certolizumab pegol (DRUG).
Who is sponsoring clinical trial NCT04123795?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04123795 being conducted?
This trial has 19 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04123795's enrollment target sits among peer trials
49 1861st of 2000 higher than 139 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI